Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website
23 Julho 2009 - 11:06AM
Business Wire
Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced the
launch of a new website, www.focusonptcl.com, dedicated to
peripheral T-cell lymphoma (PTCL). This on-line resource is
designed to provide information to patients and caregivers to aide
in the understanding of PTCL. Healthcare providers will be able to
utilize this resource to obtain clinical information, including
staging and diagnosis.
�We are delighted to see a dedicated educational effort on PTCL
for patients and healthcare providers. PTCL is a subtype of
non-Hodgkin�s lymphoma and has a unique presentation and
prognosis,� comments Judy Jones, LPC, president of the Cutaneous
Lymphoma Foundation. �The new website, www.focusonptcl.com, fills a
void and has compiled a wealth of information for patients and
physicians.�We encourage patients and physicians alike to visit the
site for information about the disease, diagnosis and various
treatment options.�
PTCL: A significant unmet need
- PTCL comprises a heterogeneous
group of aggressive mature T- and NK-cell lymphomas that accounts
for approximately 10% to 15% of new non-Hodgkin�s lymphoma (NHL)
cases per year in the U.S.
- The American Cancer Society
estimates that approximately 66,000 new cases of NHL will be
diagnosed in the U.S. in 2009
- No pharmaceutical agents are
currently FDA-approved for use in the treatment of either
first-line or relapsed or refractory PTCL
- Due to the aggressive nature of
the disease, a significant number of patients relapse or become
refractory after initial treatment
This educational resource compiles important information on the
diagnosis and treatment of PTCL into a web-based knowledge center.
The site has been designed to provide the most up-to-date medical
information to physicians and includes important information about
the disease state and potential treatments for patients, their
families and caregivers. The Company intends to maintain the
website to ensure that up-to-date information on PTCL is available
to the lymphoma community.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. The Company�s product
candidate, pralatrexate, is a selective antifolate designed to
accumulate preferentially in cancer cells. The Company recently
announced that the U.S. Food and Drug Administration (FDA) accepted
its New Drug Application (NDA) for pralatrexate for the treatment
of patients with relapsed or refractory peripheral T-cell lymphoma
for priority review and established a Prescription Drug User Fee
Act date of September 24, 2009 for a decision regarding approval of
the NDA. In addition, pralatrexate is being evaluated in patients
with non-small cell lung cancer, bladder cancer and a range of
lymphoma sub-types. Allos retains exclusive worldwide rights to
pralatrexate for all indications. The Company is headquartered in
Westminster, CO. For more information about Allos, visit
www.allos.com.
Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. In some cases, you can
identify forward-looking statements by terminology such as �may,�
�will,� �should,� �expects,� �intends,� �plans,� anticipates,�
�believes,� �estimates,� �predicts,� �projects,� �potential,�
�continue,� and other similar terminology or the negative of these
terms, but their absence does not mean that a particular statement
is not forward-looking. Such forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that may cause actual results to differ materially
from those anticipated by the forward-looking statements.
Information concerning these and other factors that may cause
actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2009 and in the Company's other periodic
reports and filings with the Securities and Exchange Commission.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
